Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy

NCT ID: NCT01828346

Last Updated: 2016-04-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 21 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-06-30
• Study Completion Date: 2015-11-30

Brief Summary

This is a dose escalation followed by dose expansion study of TL32711 in combination with 5-Azacitidine in subjects with Myelodysplastic syndrome who are naïve, have relapsed or have failed prior 5-azacitidine therapy. Pre-clinical and mechanistic studies support that 5-Azacitidine may modulate pathways that enable birinapant-mediated anti-tumor activity.

Detailed Description

This is a Phase 1b/2a, open-label, non-randomized study in male and female subjects with MDS who are naïve, refractory or have relapsed to 5-Azacitidine therapy.

Primary Objective is to determine the maximum tolerated dose (MTD), recommended Phase 2 dose, and pharmacodynamics (PD) of birinapant (TL32711) when administered in combination with 5-azacitidine (5 AZA) in subjects with myelodysplastic syndrome (MDS) who are naïve, refractory or have relapsed to 5-AZA therapy.

Secondary Objectives are to determine the clinical activity using the International Working Group (IWG) (Cheson, 2006) Response Criteria for MDS during the Phase 1b dose escalation stage of the study and in the Phase 2a expansion cohort, to determine the pharmacokinetics (PK) of birinapant when administered with 5-AZA in plasma and to assess exploratory translational biomarkers of anti-tumor activity of birinapant in combination therapy.

Conditions

Myelodysplastic Syndrome

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment

5-Azacitidine plus birinapant

Group Type: EXPERIMENTAL

Birinapant

Intervention Type: DRUG

Dose escalation part: (Drug escalation dose levels)

• Dose Level (1) - 13mg/m2 (twice a week for 3 of 4 weeks)
• Dose Level (-1) - 11 mg/m2 (twice a week for 3 of 4 weeks)
• Dose Level (2) - 13mg/m2 (twice weekly x 4 weeks)
• Dose Level (3a) - 17mg/m2 (twice weekly × 4 weeks)OR
• Dose Level (3b) - 17mg/m2 (twice a week for 3 of 4 weeks)

5-Azacitidine

Intervention Type: DRUG

Dose Level (0) - 75mg/m2 daily

Interventions

Birinapant

Dose escalation part: (Drug escalation dose levels)

• Dose Level (1) - 13mg/m2 (twice a week for 3 of 4 weeks)
• Dose Level (-1) - 11 mg/m2 (twice a week for 3 of 4 weeks)
• Dose Level (2) - 13mg/m2 (twice weekly x 4 weeks)
• Dose Level (3a) - 17mg/m2 (twice weekly × 4 weeks)OR
• Dose Level (3b) - 17mg/m2 (twice a week for 3 of 4 weeks)

Intervention Type: DRUG

5-Azacitidine

Dose Level (0) - 75mg/m2 daily

Intervention Type: DRUG

Other Intervention Names

TL32711; 5-AZA

Eligibility Criteria

Inclusion Criteria

• Men or women more than 18 years of age.
• Patients with high-risk Myelodysplastic Syndrome
• Performance status of greater or equal to 2 by the Eastern Cooperative Oncology Group (ECOG) scale.
• Subjects with high-risk MDS who are naïve to 5-Azacitidine or have previously received 5-AZA or decitabine as first-line cytotoxic therapy. Subjects with prior 5-Azacitidine therapy were evaluated to be either refractory or relapsed as determined by the Investigator, according to IWG response criteria.Subjects with relapsed or refractory disease may have only received prior 5-Azacitidine or decitabine.
• Hydroxyurea for patients with rapidly proliferative disease can be used up to 24 hours prior to therapy but not concomitantly with 5-Azacitidine.
• Adequate liver, pancreatic and renal function.
• Women of childbearing potential must have a negative serum pregnancy test at screening within 48 hours prior to the first dose
• Women of childbearing potential must agree to use 2 methods of adequate contraception

Exclusion Criteria

• Subjects with life-threatening toxicity or non tolerability to prior 5-Azacitidine therapy.
• Subjects with hypoplastic Myelodysplastic syndrome.
• Subjects with >30% bone marrow blast cells.
• Subjects with malignant hepatic tumors or secondary malignancy within 2 years
• Known diagnosis of human immunodeficiency virus or chronic active Hepatitis B or C.
• Uncontrolled hypertension
• Impaired cardiac function, uncontrolled cardiac arrhythmias despite medications,
• QT interval corrected for heart rate (QTcB) more than 480 msec
• Lack of recovery of prior adverse events to Grade ≤1 severity (National Cancer Institute Common Terminology Criteria for Adverse Events version 4) (except alopecia) due to therapy administered prior to the initiation of study drug dosing.
• Nursing or pregnant women.
• Known allergy to any of the formulation components of birinapant.
• Known or suspected hypersensitivity to 5-Azacitidine or mannitol.
• Any concurrent disease and/or medical condition that, in the opinion of the Investigator, would prevent the subject's participation.
• History of Bell's Palsy.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

TetraLogic Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Gautam Borthakur, MD

Role: PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Locations

Palo Verde Hematology Oncology

Glendale, Arizona, United States

Mayo Clinic Scottsdale

Scottsdale, Arizona, United States

California Cancer Associates for Research and Excellence

Fresno, California, United States

Mayo Clinic Jacksonville

Jacksonville, Florida, United States

Roswell Park Cancer Institute

Buffalo, New York, United States

University of Pennsylvania, Abramson Cancer Center

Philadelphia, Pennsylvania, United States

The University of Texas M.D. Anderson Cancer Center

Houston, Texas, United States

Countries

United States

Other Identifiers

TL32711-0087

Identifier Type: -

Identifier Source: org_study_id